BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23651636)

  • 1. Therapeutic destruction of insulin receptor substrates for cancer treatment.
    Reuveni H; Flashner-Abramson E; Steiner L; Makedonski K; Song R; Shir A; Herlyn M; Bar-Eli M; Levitzki A
    Cancer Res; 2013 Jul; 73(14):4383-94. PubMed ID: 23651636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
    Ibuki N; Ghaffari M; Reuveni H; Pandey M; Fazli L; Azuma H; Gleave ME; Levitzki A; Cox ME
    Mol Cancer Ther; 2014 Dec; 13(12):2827-39. PubMed ID: 25267499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
    Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
    Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
    Shi H; Kong X; Ribas A; Lo RS
    Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody.
    Wang Y; Hailey J; Williams D; Wang Y; Lipari P; Malkowski M; Wang X; Xie L; Li G; Saha D; Ling WL; Cannon-Carlson S; Greenberg R; Ramos RA; Shields R; Presta L; Brams P; Bishop WR; Pachter JA
    Mol Cancer Ther; 2005 Aug; 4(8):1214-21. PubMed ID: 16093437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
    Hong SP; Ahn SK
    Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin Receptor Substrate 1, the Hub Linking Follicle-stimulating Hormone to Phosphatidylinositol 3-Kinase Activation.
    Law NC; Hunzicker-Dunn ME
    J Biol Chem; 2016 Feb; 291(9):4547-60. PubMed ID: 26702053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2.
    Yang M; Shan X; Zhou X; Qiu T; Zhu W; Ding Y; Shu Y; Liu P
    Anticancer Agents Med Chem; 2014; 14(6):884-91. PubMed ID: 24875127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a Novel Invasion-Promoting Region in Insulin Receptor Substrate 2.
    Mercado-Matos J; Janusis J; Zhu S; Chen SS; Shaw LM
    Mol Cell Biol; 2018 Jul; 38(14):. PubMed ID: 29685905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.
    Luo L; Zhang Z; Qiu N; Ling L; Jia X; Song Y; Li H; Li J; Lyu H; Liu H; He Z; Liu B; Zheng G
    Nat Commun; 2021 May; 12(1):2699. PubMed ID: 33976188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
    Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I-stimulated insulin receptor substrate-1 negatively regulates Src homology 2 domain-containing protein-tyrosine phosphatase substrate-1 function in vascular smooth muscle cells.
    Radhakrishnan Y; Busby WH; Shen X; Maile LA; Clemmons DR
    J Biol Chem; 2010 May; 285(21):15682-95. PubMed ID: 20207740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
    Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB
    J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. METTL3 induces PLX4032 resistance in melanoma by promoting m
    Bhattarai PY; Kim G; Poudel M; Lim SC; Choi HS
    Cancer Lett; 2021 Dec; 522():44-56. PubMed ID: 34530048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.
    Huang F; Chang H; Greer A; Hillerman S; Reeves KA; Hurlburt W; Cogswell J; Patel D; Qi Z; Fairchild C; Ryseck RP; Wong TW; Finckenstein FG; Jackson J; Carboni JM
    Mol Cancer Ther; 2015 Feb; 14(2):620-30. PubMed ID: 25527633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.
    Sabbatini P; Rowand JL; Groy A; Korenchuk S; Liu Q; Atkins C; Dumble M; Yang J; Anderson K; Wilson BJ; Emmitte KA; Rabindran SK; Kumar R
    Clin Cancer Res; 2009 May; 15(9):3058-67. PubMed ID: 19383820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.
    Yang Y; Chan JY; Temiz NA; Yee D
    Horm Cancer; 2018 Dec; 9(6):371-382. PubMed ID: 30229539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST.
    Meyer K; Albaugh B; Schoenike B; Roopra A
    Mol Cell Biol; 2015 Sep; 35(17):2991-3004. PubMed ID: 26100015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.